Jun 2026 (Q2 FY26) — Aug 5, 2026
Magnite Q2 FY26 — Strong CTV Growth and Raised Full-Year Outlook
Read the full callMagnite earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 193 | +11.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 16.2 | +3.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 19.4 | +73.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
1Y: $17.88 on 17 Oct 2025 → $23.55. High $25.67 (29 Sept 2026), low $11.2 (12 Feb 2026).
Overview
Call summaries
Magnite Q2 FY26 — Strong CTV Growth and Raised Full-Year Outlook
Read the full callEvery analysed call
Financials
Net profit, year on year: +74% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 162 | 194 | 156 | 173 | 179 | 205 | 164 | 193 |
| Expenses | 147 | 154 | 157 | 151 | 154 | 153 | 157 | 162 |
| Operating profit | 15 | 40 | -1 | 22 | 25 | 52 | 8 | 31 |
| Operating margin | 9.3% | 20.7% | −0.9% | 12.7% | 13.9% | 25.3% | 4.7% | 16.2% |
| Other income | -9 | 2 | -9 | -10 | -4 | -4 | -4 | -6 |
| Interest | 7 | 5 | 5 | 5 | 5 | 4 | 5 | 6 |
| Profit before tax | 6 | 42 | -10 | 12 | 21 | 48 | 4 | 26 |
| Tax rate | 16.5% | 13.8% | 8.1% | 7.9% | 4.2% | −156.0% | −18.3% | 24.2% |
| Net profit | 5 | 36 | -10 | 11 | 20 | 123 | 4 | 19 |
| EPS ($ per share) | 0.04 | — | -0.07 | 0.08 | 0.14 | — | 0.03 | 0.14 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -316 | -341 | -395 | -394 | -525 | -684 | -661 | -517 |
| Total liabilities | 242 | 283 | 557 | 1,832 | 1,921 | 1,987 | 2,087 | 2,242 |
| Fixed assets | 33 | 24 | 24 | 34 | 45 | 47 | 69 | 109 |
| Total assets | 360 | 395 | 939 | 2,713 | 2,712 | 2,689 | 2,855 | 3,164 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -23 | 32 | -12 | 127 | 193 | 214 | 235 | 236 |
| Cash from investing | 28 | -23 | 33 | -691 | -65 | -37 | -48 | -93 |
| Cash from financing | -1 | -0 | 7 | 678 | -30 | -178 | -29 | -75 |
| Net cash flow | 4 | 8 | 29 | 113 | 96 | -0 | 157 | 70 |
| Capital expenditure | -11 | -11 | -14 | -18 | -31 | -27 | -33 | -71 |
| Free cash flow | -34 | 21 | -26 | 109 | 162 | 188 | 202 | 166 |
125 filings between Oct 24, 2025 and Oct 12, 2026.
Purchases
None
No insider bought shares.
Sales
$26.97M
52 sales by 13 insiders
90% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Also filed: 1 gift.
| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| BARRETT MICHAEL G. | — | $13.64M | Aug 6, 2026 |
| Buckley Sean Patrick | — | $2.78M | Aug 18, 2026 |
| Knopper Douglas S | — | $2.67M | Sep 17, 2026 |
| Evans Katie Seitz | — | $1.84M | Sep 11, 2026 |
| Harden Sarah Patricia | — | $1.15M | Aug 28, 2026 |
| Caine Paul | — | $1.14M | Oct 12, 2026 |
| Saltz Aaron | — | $936.4K | Sep 10, 2026 |
| Buonasera David | — | $840.6K | Sep 14, 2026 |
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 12, 2026 | Caine Paul Director | Sale 10b5-1 plan | 12,500 | $316.1K |
| Oct 1, 2026 | Gephart Brian CHIEF FINANCIAL OFFICER | Award | 64,682 | $0 |
| Oct 1, 2026 | Sullivan Haas CHIEF ACCOUNTING OFFICER | Award | 24,641 | $0 |
| Sep 17, 2026 | Caine Paul Director | Sale 10b5-1 plan | 7,500 | $198.8K |
| Sep 17, 2026 | Knopper Douglas S Director | Sale 10b5-1 plan | 37,337 | $981.2K |
| Sep 14, 2026 | Spillane Robert F Director | Sale | 10,363 | $246.2K |
| Sep 14, 2026 | Buonasera David CHIEF TECHNOLOGY OFFICER | Sale 10b5-1 plan | 1,165 | $28.0K |
| Sep 14, 2026 | Spillane Robert F Director | Option exercise | 10,363 | $53.6K |
| Sep 11, 2026 | Evans Katie Seitz See Remarks | Sale 10b5-1 plan | 13,997 | $335.9K |
| Sep 10, 2026 | Caine Paul Director | Sale 10b5-1 plan | 5,000 | $117.7K |
| Sep 10, 2026 | Saltz Aaron CHIEF LEGAL OFFICER | Sale 10b5-1 plan | 40,000 | $936.4K |
| Sep 9, 2026 | Evans Katie Seitz See Remarks | Sale 10b5-1 plan | 11,100 | $260.4K |
| Sep 8, 2026 | Evans Katie Seitz See Remarks | Sale 10b5-1 plan | 32,285 | $762.9K |
| Sep 8, 2026 | Evans Katie Seitz See Remarks | Option exercise 10b5-1 plan | 13,546 | $69.9K |
| Sep 2, 2026 | Buonasera David CHIEF TECHNOLOGY OFFICER | Sale 10b5-1 plan | 1,043 | $26.1K |
| Sep 1, 2026 | Buonasera David CHIEF TECHNOLOGY OFFICER | Sale 10b5-1 plan | 5,371 | $125.8K |
| Aug 28, 2026 | Harden Sarah Patricia Director | Sale 10b5-1 plan | 18,436 | $442.5K |
| Aug 26, 2026 | Harden Sarah Patricia Director | Sale 10b5-1 plan | 30,550 | $712.1K |
| Aug 18, 2026 | Buckley Sean Patrick See Remarks | Sale 10b5-1 plan | 2,759 | $69.0K |
| Aug 17, 2026 | Buckley Sean Patrick See Remarks | Sale 10b5-1 plan | 8,271 | $201.1K |
| Aug 15, 2026 | Day David CHIEF FINANCIAL OFFICER | Tax withheld | 14,170 | $350.4K |
| Aug 15, 2026 | Evans Katie Seitz See Remarks | Tax withheld | 11,204 | $277.1K |
| Aug 15, 2026 | Buonasera David CHIEF TECHNOLOGY OFFICER | Tax withheld | 8,102 | $200.4K |
| Aug 15, 2026 | Buckley Sean Patrick See Remarks | Tax withheld 10b5-1 plan | 11,715 | $289.7K |
| Aug 15, 2026 | Saltz Aaron CHIEF LEGAL OFFICER | Tax withheld | 5,627 | $139.2K |
| Aug 15, 2026 | Gephart Brian CHIEF ACCOUNTING OFFICER | Tax withheld | 3,789 | $93.7K |
| Aug 15, 2026 | BARRETT MICHAEL G. CEO | Tax withheld | 10,404 | $257.3K |
| Aug 14, 2026 | Caine Paul Director | Sale 10b5-1 plan | 7,500 | $187.5K |
| Aug 13, 2026 | Day David CHIEF FINANCIAL OFFICER | Gift | 26,258 | $0 |
| Aug 10, 2026 | Gephart Brian CHIEF ACCOUNTING OFFICER | Sale | 12,479 | $308.0K |
| Aug 10, 2026 | Lam Rachel Director | Sale | 10,000 | $241.6K |
| Aug 10, 2026 | Caine Paul Director | Sale 10b5-1 plan | 5,000 | $121.8K |
| Aug 6, 2026 | Buckley Sean Patrick See Remarks | Sale 10b5-1 plan | 47,942 | $1.20M |
| Aug 6, 2026 | BARRETT MICHAEL G. CEO | Option exercise 10b5-1 plan | 293,968 | $1.71M |
| Aug 6, 2026 | Buonasera David CHIEF TECHNOLOGY OFFICER | Sale 10b5-1 plan | 871 | $21.8K |
| Aug 6, 2026 | Buonasera David CHIEF TECHNOLOGY OFFICER | Sale 10b5-1 plan | 2,602 | $62.4K |
| Aug 6, 2026 | Buonasera David CHIEF TECHNOLOGY OFFICER | Sale 10b5-1 plan | 4,176 | $95.3K |
| Aug 6, 2026 | Buckley Sean Patrick See Remarks | Sale 10b5-1 plan | 19,237 | $442.5K |
| Aug 6, 2026 | Buckley Sean Patrick See Remarks | Option exercise 10b5-1 plan | 28,703 | $399.0K |
| Aug 6, 2026 | Evans Katie Seitz See Remarks | Sale 10b5-1 plan | 20,000 | $480.0K |
| Aug 6, 2026 | Evans Katie Seitz See Remarks | Option exercise 10b5-1 plan | 20,000 | $103.2K |
| Aug 6, 2026 | Knopper Douglas S Director | Sale 10b5-1 plan | 37,337 | $848.3K |
| Aug 6, 2026 | BARRETT MICHAEL G. CEO | Sale 10b5-1 plan | 293,968 | $6.68M |
| Jul 15, 2026 | BARRETT MICHAEL G. CEO | Sale 10b5-1 plan | 38,596 | $785.4K |
| Jul 15, 2026 | BARRETT MICHAEL G. CEO | Option exercise 10b5-1 plan | 38,596 | $223.9K |
| Jul 10, 2026 | Caine Paul Director | Sale 10b5-1 plan | 5,000 | $103.2K |
| Jul 7, 2026 | Buckley Sean Patrick See Remarks | Sale 10b5-1 plan | 19,233 | $404.5K |
| Jul 7, 2026 | Buonasera David CHIEF TECHNOLOGY OFFICER | Sale 10b5-1 plan | 1,224 | $25.7K |
| Jul 1, 2026 | Buonasera David CHIEF TECHNOLOGY OFFICER | Sale 10b5-1 plan | 9,376 | $187.5K |
| Jun 29, 2026 | BARRETT MICHAEL G. CEO | Sale 10b5-1 plan | 75,000 | $1.46M |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Free account. Everything above stays public.
Write why you follow MAGNITE, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading